Basilea PharmaceuticaXSWX:BSLN -0.55%59 Median PS Value is CHF63.72 as of Jul. 12, 2026, which is 100% below its 10-year median of 0.47. GuruFocus rates XSWX:BSLN with a GF Score™ of 59/100 and a GF Value™ of CHF57.66 (Fairly Valued). The stock has 4 warning signs investors should review. Among 278 Biotechnology companies, Basilea Pharmaceutica ranks worse than 66.19% on this metric.
This valuation method assumes that the stock valuation will revert to its historical (10-Year) median in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Basilea Pharmaceutica's Median PS Value or its related term are showing as below:
XSWX:BSLN'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.24 Med: 0.47 Max: 0.86
Current: 0.86
During the past 13 years, the highest Price to Median PS Value of Basilea Pharmaceutica was 0.86. The lowest was 0.24. And the median was 0.47.
XSWX:BSLN's Price-to-Median-PS-Value is ranked worse than 66.19% of 278
companies
in the Biotechnology industry
Industry Median: 0.645
vs XSWX:BSLN: 0.86
Basilea Pharmaceutica (XSWX:BSLN) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Basilea Pharmaceutica's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
54.70
/
63.72
=
0.86
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Basilea Pharmaceutica Median PS Value Related Terms
Basilea Pharmaceutica Median PS Value Historical Data
* Premium members only.
The historical data trend for Basilea Pharmaceutica's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:BSLN vs VRTX, REGN, ALNY: Median PS Value Comparison
For the Biotechnology subindustry, Basilea Pharmaceutica's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Basilea Pharmaceutica Price-to-Median-PS-Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Basilea Pharmaceutica's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Basilea Pharmaceutica's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 3.7471.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Basilea Pharmaceutica's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was CHF17.005.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Basilea Pharmaceutica (XSWX:BSLN) has a Median PS Value of CHF63.72 as of Jul. 12, 2026. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Basilea Pharmaceutica and its competitors. This is 13457% above median its historical median of 0.47. Over the past decade, Basilea Pharmaceutica's Median PS Value has ranged from 0.24 to 0.86. According to the industry distribution chart, Basilea Pharmaceutica ranks #184 out of 278 companies in the Biotechnology industry, placing it in the top 66.2%.
Is Basilea Pharmaceutica's Median PS Value too high?
Basilea Pharmaceutica's current Median PS Value of CHF63.72 is 13457% above median its 10-year median of 0.47. Over the past 10 years, this metric has ranged from a low of 0.24 to a high of 0.86. Based on the distribution chart, Basilea Pharmaceutica ranks #184 out of 278 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Basilea Pharmaceutica has a GF Score™ of 59/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Basilea Pharmaceutica's Median PS Value compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Basilea Pharmaceutica ranks #184 out of 278 companies for Median PS Value. This places Basilea Pharmaceutica in the lower half of its industry. The industry median Median PS Value is 0.65. Historically, Basilea Pharmaceutica's own Median PS Value has ranged from 0.24 to 0.86 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Median PS Value for a Biotechnology company?
The median Median PS Value among Biotechnology companies is 0.65, based on 278 companies in the industry. Companies in the top quartile (top 25%) have a Median PS Value significantly above this median, while those in the bottom quartile fall well below. However, Median PS Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Median PS Value mean?
A high Median PS Value can signal that a stock is expensive relative to its fundamentals. Median price-sales value is the stock value based on a company's 10-year median price-sales ratio, View historical data on Basilea Pharmaceutica and its competitors. For the Biotechnology industry, the median Median PS Value is 0.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Basilea Pharmaceutica's current Median PS Value is CHF63.72, which is 13457% above median its own 10-year median of 0.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Basilea Pharmaceutica stock overvalued right now?
Based on GuruFocus' analysis, Basilea Pharmaceutica (XSWX:BSLN) is currently considered Fairly Valued. The stock's GF Value™ is CHF57.66, compared to a current price of CHF54.70 — trading 5.1% below its estimated fair value. The current Median PS Value is CHF63.72, which is 13457% above median its 10-year median of 0.47. Basilea Pharmaceutica's overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Median PS Value calculated?
Median PS Value is calculated from a company's financial statements. For Basilea Pharmaceutica (XSWX:BSLN), the current Median PS Value is CHF63.72 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Basilea Pharmaceutica (XSWX:BSLN) Overvalued in 2026?
Based on GuruFocus' analysis, Basilea Pharmaceutica stock appears to be undervalued.
The current stock price of CHF54.70 is trading 5.1% below its estimated GF Value™ of CHF57.66.
GuruFocus considers Basilea Pharmaceutica to be Fairly Valued.
Key valuation signals for XSWX:BSLN:
Median PS Value: CHF63.72 (13457% above median its 10-year median of 0.47)
GF Value™: CHF57.66 vs. price of CHF54.70 (5.1% below fair value)
No single metric tells the full story. See the XSWX:BSLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.
59GF Score
Get the complete analysis for XSWX:BSLN
Median PS Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:BSLN has been successfully added to your 
